Advances in Genomics and Molecular Diagnostics in Gynecological Pathology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 15 December 2025 | Viewed by 1265
Special Issue Editors
Interests: molecular pathology; gynecological cancer; female reproductive tract; breast cancer
2. INSERM U955, Université Paris Est Créteil, 94000 Créteil, France
Interests: molecular pathology; targeted therapies; biomarkers; non-coding RNAs
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Recent advancements in the genomics characterization and molecular pathology of gynecological cancers have significantly enhanced our understanding of tumor development and impacted our diagnostic approaches and identification of therapeutic biomarkers. Germline and somatic tumor testing in gynecological neoplasms requires comprehensive genomic profiling to identify mutations, which can inform targeted therapy and familial risk assessment.
For ovarian cancer, molecular profiling has identified key mutations such as TP53, BRCA1/2, and homologous recombination deficiency, which are critical for guiding poly(ADP-ribose) polymerase inhibitors. The Cancer Genome Atlas has provided a comprehensive genomic landscape, identifying recurrent somatic mutations and copy number alterations that inform targeted therapies. The National Comprehensive Cancer Network (NCCN) guidelines recommend molecular classification of endometrial cancer into four subtypes. Identifying HER2 amplification in endometrial serous carcinomas has opened avenues for trastuzumab therapy. Cervical cancer management has also benefited from molecular insights, particularly programmed death ligand 1 (PD-L1) immunohistochemistry, to predict response to immune checkpoint inhibitors.
New molecular targets, such as POLE mutations, and analysis of the expression of antibody-conjugated targets, such as HER2, TROP2, and NECTIN2, are making their way into daily clinical practice. Therefore, the integration of molecular pathology into the clinical management of gynecological cancers is rapidly evolving, driven by advances in genomic technologies and a deeper understanding of tumor biology. This Special Issue aims to bring together cutting-edge original research and reviews that focus on the advances in molecular pathology of gynecological cancers, including, but not limited to, ovarian, endometrial, cervical, and vulvar cancers. By exploring the latest advances in tumor genomics, molecular diagnostics, biomarkers, therapeutic targets, and personalized medicine, this Special Issue provides a comprehensive overview of how molecular pathology shapes the future of gynecological oncology.
Dr. Maria Olinca
Dr. Radu Pirlog
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor genomics
- molecular diagnosis
- targeted therapies
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
